ILMN : Analysis & Opinions

  1. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  2. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  3. Market Wrap for Wednesday, July 24: Stocks Largely Lower Despite ...

    July 24, 2013
    Despite a report which showed that new home sales in the U.S. are at a 5-Year high, the stock market was largely lower on ...
  4. Illumina, Teva Spread NIPT in Israel - Analyst Blog

    July 3, 2013
    Verinata Health, a division of Illumina Inc., entered into an exclusive agreement with Teva Pharmaceutical Industries Ltd.
  5. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  6. Thermo Steps Up And Seals A Deal For Life Technologies

    April 19, 2013
    Speculation has been all over the place for an M&A with LifeTech, but the final announcement is consistent with my expectations.
  7. Affymetrix Links Up with DNA Link - Analyst Blog

    February 11, 2013
    Genetic products company, Affymetrix Inc. (AFFX), inked a 'Powered by Affymetrix' ("PbA") Program agreement with Korea-based ...
  8. Affymetrix's 4Q EPS In Line - Analyst Blog

    February 1, 2013
    Global genetic devices maker, Affymetrix Inc.'s (AFFX) fourth-quarter 2012 adjusted loss of 2 cents per share was in line ...
  9. Illumina Posts an Impressive 4Q - Analyst Blog

    January 29, 2013
    Illumina (ILMN) reported fourth quarter 2012 adjusted earnings per share ("EPS") of 42 cents, beating the Zacks Consensus ...
  10. Has Roche Said "Nein" To Illumina's Asking Price Once More?

    January 7, 2013
    Roche may have walked away from Illumina for good.
  11. Nasdaq Stocks, Including Bed Bath & Beyond, Making Big Moves ...

    December 20, 2012
    Currently, the Nasdaq is trading down 0.4%, the S&P 500 is unchanged and the Dow has declined 0.1%. The Nasdaq Composite ...
  12. Illumina and Other Technology Stocks Making Big Moves on December ...

    December 20, 2012
    The Nasdaq is trading down 0.4%, the S&P 500 remains relatively unchanged and the Dow is down 0.1% so far today. The technology ...
  13. Illumina and More Big Movers in Technology on November 26, 2 ...

    November 26, 2012
    The market is currently down, with the Nasdaq slipping 0.4%, the S&P 500 declining 0.7% and the Dow falling 0.8%. The technology ...
  14. Mixed 3Q for Genomic Health - Analyst Blog

    November 8, 2012
    Genomic Health (GHDX) reported third quarter 2012 net income of $3.7 million, up from $3.2 million in the year-ago period. ...
  15. Will It Be Even Harder For Life Tech To Muddle Through In 2013?

    November 5, 2012
    Life Tech has the right technology, but 2013 could be a challenging year for the sector.
  16. Nasdaq Stocks, Including Illumina, Making Big Moves on October ...

    October 2, 2012
    Currently, the Nasdaq has increased 0.4%, the S&P 500 is up 0.1% and the Dow is trading down 0.2%. The recent surge in popularity ...
  17. VMware and Other Big Movers In Technology on October 2, 2012

    October 2, 2012
    The Nasdaq has risen 0.4%, the S&P 500 has moved up 0.1% and the Dow has slipped 0.2% so far today. The technology sector ...
  18. AFFX Boosts Enterprise Mobility - Analyst Blog

    September 4, 2012
    Genetic products company Affymetrix Inc. (AFFX) recently announced that iPass Inc. (IPAS), the leading global provider of ...
  19. Agilent Seeing Tougher Conditions, But Still A Quality Pick

    August 17, 2012
    Agilent's end markets have weakened, but the company looks well-positioned for the long term.
  20. Genomic Health Beats on EPS - Analyst Blog

    August 9, 2012
    Genomic Health (GHDX) reported net income of $1.8 million, lower than $2.3 million in the year-ago period. The company incurred ...
  21. Is There Enough Growth To Really Push Life Technologies?

    June 29, 2012
    Life Technologies isn't the growth stock people think it is, but at the right price it's a good holding.
  22. Life Tech Remains Neutral - Analyst Blog

    June 28, 2012
    We reiterate our Neutral recommendation on Life Technologies Corporation (LIFE) with a target price of $46.00. Life Technologies ...
  23. Medicine Gets Personalized

    June 28, 2012
    With our population continuing to age and grow, innovation in the healthcare sector will need to move just as fast. One such ...
  24. Qiagen Expands NGS Portfolio - Analyst Blog

    June 26, 2012
    Qiagen Inc., (QGEN) is all set to jump in the next-generation sequencing (NGS) bandwagon and plans to invest big to serve ...
  25. Biggest Technology Sector Movers for June 22, 2012

    June 22, 2012
    The market is doing well so far today. The Nasdaq is up 0.5%; the S&P 500 is up 0.3%; and the Dow has climbed 0.5%. The technology ...
  26. Genomic Health Beats Estimates - Analyst Blog

    May 3, 2012
    Genomic Health Beats Estimates - Analyst Blog
  27. Biotech Trends: Analysts Expect Big Growth for Genetic Testing ...

    March 13, 2012
    Analysts expect genetic testing to bring in $15 - $25 billion per year for the next decade, with an expected annual growth ...
  28. A Pause In Electronic Test Gives Investors Another Chance With ...

    February 17, 2012
    Agilent pauses with the telecom slowdown.
  29. Neogen Is Almost Cheap

    December 30, 2011
    Neogen has to do more to validate this price.
  30. Will Qiagen's Restructuring Address The Real Problems?

    November 30, 2011
    Will Qiagen's Restructuring Address The Real Problems?
  31. Renewed Realism May Make Life Tech A Buy

    November 30, 2011
    It may be time to consider Life Tech as a good blue-chip play in the health-care sector.
  32. If The Economy Holds, Agilent Is A Buy

    November 23, 2011
    Agilent seems too cheap for its qualities.
  33. PerkinElmer Adds High-End Tools To Its Box

    September 13, 2011
    Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
  34. Agilent Beaten Down To Bargain

    August 17, 2011
    Agilent continues to deliver the results, quarter after quarter.
  35. Affymetrix's Downward Spiral Continues

    July 7, 2011
    Affymetrix continues to flounder with unexciting technology.
  36. Roche Noise May Be A Buyer's Best Friend

    December 22, 2010
    A spate of bad news may have Roche in great value shape.
  37. Thermo Fisher Pays A High Price For Quality

    December 15, 2010
    Thermo Fisher makes a very reasonable purchase but pays a price to do so.
  38. The Stock-Split Portfolio

    December 6, 2010
    Many investors debate the merits of a stock split, but the bottom line doesn't lie. Find out how companies who split their ...
  39. Limited Love For Life Sciences

    November 18, 2010
    Recent life sciences IPOs have landed with thud, which is a drastic contrast to the trends that were occuring just 10 years ...
  40. A Fistfull Of Life Sciences

    October 29, 2010
    The life sciences field is showing encouraging growth and mostly reasonable valuations.
  41. Roche Needs A Shot Of Adrenalin

    October 18, 2010
    Roche has a lot of great value characteristics, but value will wither in the absence of growth.
  42. The Next-Gen Sequencing Pot Keeps Bubbling

    August 23, 2010
    Last week saw two major developments in one of the fastest-growing arenas of life science.
  43. Thermo Fisher Gets Cool Reception

    July 29, 2010
    Wall Street did not like Thermo's guidance, but that could be an opportunity for patient investors looking for a low-beta ...
  44. Bringing Biotech To The Barnyard

    June 17, 2010
    Human medicine isn't the only arena where genomics is sparking a revolution. Agriculture could be the next way for investors ...
  45. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  46. Stock Splits Worth A Look

    May 11, 2009
    What does the decline in stock splits mean for investors?
  47. Affymetrix Misses Revenue Again And Again

    October 16, 2008
    Affymetrix missed revenue for the third consecutive quarter and blamed weak sales on a weak market - something competitors ...
  48. No deCODE Needed - Just Say No

    September 22, 2008
    DeCODE Genetics is a lesson in why investors should stay clear of micro-cap biotech companies - no matter how promising they ...
  49. Getting Technical With Biotech

    July 11, 2008
    Watch as a blend of technical and fundamental analysis reveals hidden gems in this unpredictable sector.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center